Stockscreener 앱 받기
69.28
0.72%
-0.50
시간 외 거래:
70.70
1.42
+2.05%
Anaptysbio Inc 주식(ANAB)의 최신 뉴스
AnaptysBio (NASDAQ:ANAB) Reaches New 52-Week HighHere's Why - MarketBeat
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? - Yahoo Finance
Piper Sandler Maintains AnaptysBio(ANAB.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation - MSN
ANAB Maintained by Piper Sandler -- Price Target Lowered to $93 - GuruFocus
AnaptysBio CEO to appear at royalty company virtual conference - Stock Titan
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference - GlobeNewswire
Biotech Momentum Builds Around AnaptysBio Shift - Kalkine Media
Piper Sandler Issues Pessimistic Forecast for AnaptysBio (NASDAQ:ANAB) Stock Price - MarketBeat
AnaptysBio (ANAB) Is Up 13.4% After Court Upholds Jemperli Royalty Rights In Tesaro Dispute - Yahoo Finance
AnaptysBio stock rallies as Delaware court tosses Tesaro breach claim - MSN
AnaptysBio, Inc. (ANAB) may report negative earnings: Know the trend ahead of Q1 release - MSN
AnaptysBio (NASDAQ:ANAB) Passes Minervini Trend Template and High Growth Momentum Screen - ChartMill
AnaptysBio, Inc. (NASDAQ:ANAB) Short Interest Down 14.7% in April - MarketBeat
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
AnaptysBio rises after completing First Tracks spinoff - MSN
Director Susannah Gray receives 11,250 RSUs at AnaptysBio (ANAB) - Stock Titan
Barclays Initiates Coverage of AnaptysBio (ANAB) with Overweight Recommendation - MSN
ANAB SEC FilingsAnaptysbio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
AnaptysBio (ANAB) surges 14.8%: Is this an indication of further gains? - MSN
Rare skin disease drug study appears in NEJM Evidence before FDA date - Stock Titan
AnaptysBio (NASDAQ: ANAB) details spin-off, pay and board changes - Stock Titan
Fenwick Secures Chancery Court Victory for AnaptysBio in Licensing Dispute - fenwick.com
ANAB Rated Outperform by Leerink Partners -- Price Target Raised to $85 - GuruFocus
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year HighTime to Buy? - MarketBeat
Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence - Sahm
Why Is AnaptysBio Stock Soaring Monday?AnaptysBio (NASDAQ:ANAB) - Benzinga
AnaptysBio (NASDAQ:ANAB) Trading 11.2% HigherTime to Buy? - MarketBeat
GSK subsidiary Tesaro, AnaptysBio provide update on contract claim litigation (GSK:NYSE) - Seeking Alpha
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
AnaptysBio (ANAB) Surges 14.8%: Is This an Indication of Further Gains? - Yahoo Finance
GSK (NYSE: GSK) outlines TESARO–AnaptysBio dostarlimab litigation status and Jemperli growth - Stock Titan
AnaptysBio (ANAB) Expected to Announce Earnings on Monday - MarketBeat
GSK Subsidiary Wins Motion Against AnaptysBio in Contract Dispute - GuruFocus
GSK Subsidiary TESARO Faces Setback in AnaptysBio Litigation, Jemperli Growth Remains Strong - AskTraders
Court favors AnaptysBio dismissing anticipatory breach claim - The Pharma Letter
GSK subsidiary wins dismissal of AnaptysBio anticipatory breach claim (GSK:NYSE) - Seeking Alpha
TESARO, a GSK subsidiary, provides update on AnaptysBio, Inc. litigation - GSK
GSK unit wins partial dismissal in dostarlimab licence dispute with AnaptysBio - Proactive financial news
US court rules against GSK in dispute with AnaptysBio - Sharecast.com
GSK says unit Tesaro's claim for declaratory judgment against AnaptysBio unchanged - marketscreener.com
AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio Completes Spin-Off of First Tracks Biotherapeutics: Key Financial Impacts and Pro Forma Results - Minichart
Delaware court dismisses Tesaro breach claim against AnaptysBio By Investing.com - Investing.com Australia
AnaptysBio (NASDAQ:ANAB) Stock Rating Upgraded by Wall Street Zen - MarketBeat
GSK Faces Legal Setback as AnaptysBio Wins Court Ruling - GuruFocus
0.14%
0.48%
자본화:
|
볼륨(24시간):